Quick Takeaways
- MPM BioVentures 2014, L.P. filed SCHEDULE 13D/A for REPARE THERAPEUTICS INC. Common Shares (RPTX).
- Disclosed ownership: 5.1%.
- Date of event: 13 Jan 2025.
MPM BioVentures 2014, L.P. - 13 Jan 2025 SCHEDULE 13D/A Report for REPARE THERAPEUTICS INC. Common Shares (RPTX)
- Filing Manager
- MPM BioVentures 2014, L.P.
- Reporting Manager
- ANSBERT GADICKE
- Symbol
- RPTX
- Shares outstanding
- 42,145,392 shares
- Disclosed Ownership
- 2,149,415 shares
- Ownership
- 5.1%
- Form type
- SCHEDULE 13D/A
- Filing time
- 15 Jan 2025, 18:43:01 UTC
- Date of event
- 13 Jan 2025
- Previous filing
- 06 Jan 2025
- Next filing
- 31 Jan 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MPM BioVentures 2014, L.P. disclosed 5.1% ownership in REPARE THERAPEUTICS INC. Common Shares (RPTX) on 13 Jan 2025."
What Changed
- Previous schedule filing date: 06 Jan 2025.
- Current filing was accepted on 15 Jan 2025, 18:43.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (11)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P. | 2.7% | 1,127,549 | 1,127,549 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P. | 0001609492 |
| MPM BioVentures 2014 (B), L.P. | 0.2% | 75,206 | 75,206 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014 (B), L.P | 0001609493 |
| MPM Asset Management Investors BV2014 LLC | 0.1% | 38,809 | 38,809 | 0 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC | 0001609495 |
| UBS Oncology Impact Fund L.P. | 2.1% | 907,851 | 907,851 | 0 | /s/ Ansbert Gadicke | Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P. | 0001691428 |
| MPM BioVentures 2014 GP LLC | 2.8% | 1,202,755 | 0 | 1,202,755 | /s/ Ansbert Gadicke | Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC | 0001765091 |
| MPM BioVentures 2014 LLC | 2.9% | 1,241,564 | 0 | 1,241,564 | /s/ Ansbert Gadicke | Managing Director | 0001765021 |
| Oncology Impact Fund (Cayman) Management L.P. | 2.1% | 907,851 | 0 | 907,851 | /s/ Ansbert Gadicke | Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P. | 0001721036 |
| MPM BioImpact LLC | 2.1% | 907,851 | 0 | 907,851 | /s/ Ansbert Gadicke | Managing Partner | 0001687078 |
| ANSBERT GADICKE | 5.1% | 2,149,415 | 0 | 2,149,415 | /s/ Ansbert Gadicke | Ansbert Gadicke | 0001134655 |
| LUKE EVNIN | 2.9% | 1,241,564 | 0 | 1,241,564 | /s/ Luke Evnin | Luke Evnin | 0001134657 |
| Todd Foley | 2.9% | 1,241,564 | 0 | 1,241,564 | /s/ Todd Foley | Todd Foley | 0001473930 |